299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02934139 (ClinicalTrials.gov)	October 2016	10/10/2016	MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of N91115 in Healthy Subjects	Cystic Fibrosis	Drug: Cavosonstat;Other: Placebo	Nivalis Therapeutics, Inc.	NULL	Completed	18 Years	55 Years	All	32	Phase 1	United States
2	NCT02724527 (ClinicalTrials.gov)	April 2016	11/3/2016	Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 for Efficacy and Safety in Patients With CF Heterozygous for F508del-CFTR + Gating Mutation Being Treated With Ivacaftor	Cystic Fibrosis	Drug: Cavosonstat;Drug: Placebo	Nivalis Therapeutics, Inc.	NULL	Active, not recruiting	18 Years	N/A	Both	19	Phase 2	United States
3	NCT02589236 (ClinicalTrials.gov)	November 2015	26/10/2015	Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor	Cystic Fibrosis	Drug: Cavosonstat;Drug: Placebo	Nivalis Therapeutics, Inc.	Medidata Solutions	Completed	18 Years	N/A	All	138	Phase 2	United States